154 related articles for article (PubMed ID: 25812504)
1. [A case of stage IV breast cancer with long-term partial response treated with tri-weekly paclitaxel plus bevacizumab].
Okamoto A; Nakatsukasa K; Fujita Y; Sugimoto R; Sakaguchi K; Taguchi T
Gan To Kagaku Ryoho; 2015 Mar; 42(3):343-6. PubMed ID: 25812504
[TBL] [Abstract][Full Text] [Related]
2. [A case of stage IV breast cancer with improved cancer pain using bevacizumab and paclitaxel].
Ishiyama T; Jinguu A; Matsumoto H; Kikuchi J; Suzuki T
Gan To Kagaku Ryoho; 2015 Mar; 42(3):347-9. PubMed ID: 25812505
[TBL] [Abstract][Full Text] [Related]
3. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S
Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309
[TBL] [Abstract][Full Text] [Related]
4. Locally advanced breast cancer with bleeding - two cases effectively treated with bevacizumab plus weekly paclitaxel.
Ishizuna K; Ninomiya J; Ogawa T; Kojima M; Kawashima M; Nozaki M; Yamagishi H; Ueda Y
Gan To Kagaku Ryoho; 2014 May; 41(5):637-40. PubMed ID: 24917012
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.
Fountzilas G; Kourea HP; Bobos M; Televantou D; Kotoula V; Papadimitriou C; Papazisis KT; Timotheadou E; Efstratiou I; Koutras A; Pentheroudakis G; Christodoulou C; Aravantinos G; Miliaras D; Petraki K; Papandreou CN; Papakostas P; Bafaloukos D; Repana D; Razis E; Pectasides D; Dimopoulos AM
Anticancer Res; 2011 Sep; 31(9):3007-18. PubMed ID: 21868552
[TBL] [Abstract][Full Text] [Related]
6. [A case of bone marrow carcinomatosis with disseminated intravascular coagulation arising from breast cancer successfully treated with paclitaxel plus bevacizumab].
Kawai H; Sugimoto R; Miyauchi S; Yoshida R; Waki N; Hirayama S; Ishizaki M; Nishi H; Yamashita K
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1957-9. PubMed ID: 25731388
[TBL] [Abstract][Full Text] [Related]
7. [Usefulness of bevacizumab combination chemotherapy for advanced breast cancer].
Aomatsu N; Kashiwagi S; Morisaki T; Ishihara S; Asano Y; Watanabe M; Noda S; Kawajiri H; Takashima T; Onoda N; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2393-5. PubMed ID: 24394123
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Gonzalez-Martin A; Gladieff L; Tholander B; Stroyakovsky D; Gore M; Scambia G; Kovalenko N; Oaknin A; Ronco JP; Freudensprung U; Pignata S;
Eur J Cancer; 2013 Dec; 49(18):3831-8. PubMed ID: 24007819
[TBL] [Abstract][Full Text] [Related]
9. First-line bevacizumab-paclitaxel in 220 patients with metastatic breast cancer: results from the AVAREG study.
Dank M; Budi L; Piko B; Mangel L; Erfan J; Cseh J; Ruzsa A; Landherr L
Anticancer Res; 2014 Mar; 34(3):1275-80. PubMed ID: 24596372
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report.
Ishizuna K; Ninomiya J; Kojima M; Kawashima M; Nozaki M; Yamagishi H; Ueda Y; Oya M
BMC Res Notes; 2013 Jul; 6():254. PubMed ID: 23830415
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancer.
Hata A; Katakami N; Tanaka K; Takeshita J; Matsumoto T; Monden K; Nagata K; Masago K; Kaji R; Fujita S; Tachikawa R; Otsuka K; Otsuka K; Tomii K
Anticancer Res; 2014 Jan; 34(1):275-81. PubMed ID: 24403474
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of bevacizumab in combination with paclitaxel for metastatic breast cancer].
Suzuki S; Sakurai K; Nagashima S; Hara Y; Amano S; Enomoto K; Makishima M
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1289-91. PubMed ID: 25335720
[TBL] [Abstract][Full Text] [Related]
14. [Bi-weekly nab-paclitaxel and trastuzumab therapy effective against recurrent breast cancer with multiple lung metastases in elderly patient who had previously undergone two chemotherapeutic regimens for treatment of metastatic disease-a case Report].
Sakurai T; Jinta E; Suzuma T; Yoshimura G; Umemura T; Sakurai T
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1703-6. PubMed ID: 23152023
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series.
Labidi SI; Bachelot T; Ray-Coquard I; Mosbah K; Treilleux I; Fayette J; Favier B; Galy G; Blay JY; Guastalla JP
Clin Breast Cancer; 2009 May; 9(2):118-21. PubMed ID: 19433393
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
[TBL] [Abstract][Full Text] [Related]
17. [A case of triple-negative breast cancer responding to multidisciplinary treatment containing bevacizumab].
Noma M; Ohara M; Imaoka Y; Mashima H; Mizota S; Okimoto S; Takakura Y; Oishi K; Kohashi T; Ikeda S; Fudaba Y; Matsugu Y; Ishimoto T; Nakahara H; Urushihara T; Itamoto T; Doi M; Nishisaka T
Gan To Kagaku Ryoho; 2014 Apr; 41(4):483-6. PubMed ID: 24743365
[TBL] [Abstract][Full Text] [Related]
18. [A complete response following treatment with Paclitaxel and bevacizumab for metastatic breast cancer].
Tsubota Y; Sueoka N; Yamamoto D
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1954-6. PubMed ID: 25731387
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer.
Seidman AD; Conlin AK; Bach A; Moynahan ME; Lake D; Forero A; Wright GS; Hackney MH; Clawson A; Norton L; Hudis CA
Clin Breast Cancer; 2013 Aug; 13(4):239-246.e1. PubMed ID: 23829890
[TBL] [Abstract][Full Text] [Related]
20. [A Case of Recurrent Breast Cancer with Carcinomatous Pleurisy Successfully Treated with Paclitaxel and Bevacizumab after Radical Mastectomy].
Sakaguchi N; Moriya T; Yamazaki T; Yamagishi Y; Hasegawa S; Tsuda H; Hase K; Yamamoto J
Gan To Kagaku Ryoho; 2015 Jun; 42(6):751-3. PubMed ID: 26199251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
